Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, United States
Shuntai Zhou
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, United States; UNC Center For AIDS Research, University of North Carolina, Chapel Hill, United States
Yinyan Xu
Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, United States
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, United States; UNC Center For AIDS Research, University of North Carolina, Chapel Hill, United States
Daniel R MacMillan
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
Olivia Council
Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, United States; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, United States
Jennifer Kirchherr
Department of Medicine, University of North Carolina, Chapel Hill, United States
Julia M Sung
Department of Medicine, University of North Carolina, Chapel Hill, United States; UNC HIV Cure Center, University of North Carolina, Chapel Hill, United States
Department of Urology, University of California San Francisco, San Francisco, United States; Gladstone Institute of Virology and Immunology, San Francisco, United States
Adaora A Adimora
Department of Medicine, University of North Carolina, Chapel Hill, United States
Sarah Joseph
Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, United States; UNC HIV Cure Center, University of North Carolina, Chapel Hill, United States
JoAnn D Kuruc
Department of Medicine, University of North Carolina, Chapel Hill, United States; UNC HIV Cure Center, University of North Carolina, Chapel Hill, United States
Cynthia L Gay
Department of Medicine, University of North Carolina, Chapel Hill, United States; UNC HIV Cure Center, University of North Carolina, Chapel Hill, United States
David M Margolis
Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, United States; UNC Center For AIDS Research, University of North Carolina, Chapel Hill, United States; Department of Medicine, University of North Carolina, Chapel Hill, United States; UNC HIV Cure Center, University of North Carolina, Chapel Hill, United States
Nancie Archin
Department of Medicine, University of North Carolina, Chapel Hill, United States; UNC HIV Cure Center, University of North Carolina, Chapel Hill, United States
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada; Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
Ronald Swanstrom
Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, United States; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, United States; UNC Center For AIDS Research, University of North Carolina, Chapel Hill, United States; UNC HIV Cure Center, University of North Carolina, Chapel Hill, United States
Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, United States; Department of Medicine, University of North Carolina, Chapel Hill, United States; UNC HIV Cure Center, University of North Carolina, Chapel Hill, United States
HIV-1-specific CD8+ T cells are an important component of HIV-1 curative strategies. Viral variants in the HIV-1 reservoir may limit the capacity of T cells to detect and clear virus-infected cells. We investigated the patterns of T cell escape variants in the replication-competent reservoir of 25 persons living with HIV-1 (PLWH) durably suppressed on antiretroviral therapy (ART). We identified all reactive T cell epitopes in the HIV-1 proteome for each participant and sequenced HIV-1 outgrowth viruses from resting CD4+ T cells. All non-synonymous mutations in reactive T cell epitopes were tested for their effect on the size of the T cell response, with a≥50% loss defined as an escape mutation. The majority (68%) of T cell epitopes harbored no detectable escape mutations. These findings suggest that circulating T cells in PLWH on ART could contribute to control of rebound and could be targeted for boosting in curative strategies.